Table 3.

Characteristics and fluconazole treatment features in six patients infected with C. glabrata that acquired in vitro resistance under fluconazole treatment.

Patient no.	Age (yr)/sex	Underling disease	No. of positive culture (sampling times in days)	Fluconazole treatment dosage (administration days)
1	43/M	Nephrolithiasis	3 (0, 60, 150)	200 mg (60–80)
2	42/F	Diabetes	2 (0, 30)	200 mg (0–28)
3	53/F	Asthma (corticotherapy)	5 (0, 150, 220, 250, 280)	150 mg (120–135), 100 mg (150–165), 400 mg (225–232), 200 mg (250–257)
4	72/F	Nephrolithiasis and diabetes	3 (0, 130, 446)	400 mg (130–160)